Imugene Ltd has released a press release.
Prestigious Research Journal Publish HER-Vaxx Phase 1B Data
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Appendix 4C - quarterly
- Imugene announces clinical milestone for HER-Vaxx
- Imugene Oncolytic Virus Presentation at AACR 2021 Meeting
- Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX
- S&P DJI Announces March 2021 Quarterly Rebalance
Later from Imugene
- Investor Presentation
- FDA ind approval of new oncolytic virotherapy checkvacc
- Appendix 4C - Quarterly Report
- Imugene completes $90 M placement and launches $5 M SPP
- Prospectus for SPP and Placement Options Offer
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene